The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Antiplatelet Agent-Related Peptic Ulcer Disease

항혈소판제에 의한 소화성 궤양

  • Chang, Young Woon (Department of Gastroenterology, Kyung Hee University College of Medicine)
  • 장영운 (경희대학교 의과대학 소화기내과)
  • Published : 2014.06.01
⟨ Previous Next ⟩

Abstract

Antiplatelet therapies have been widely used to prevent cardiovascular diseases. However, antiplatelet agents cause gastrointestinal (GI) damage and are associated with a greater risk of gastroduodenal ulcers and life-threatening ulcer complications. The first step to reduce the GI risk of antiplatelet therapy is to assess whether the patient requires continuous antiplatelet therapy. The second step is to eliminate risk factors that may place the patient at greater GI risk such as Helicobacter pylori infection, NSAID use, steroid ingestion, and smoking. Continuous aspirin therapy plus a powerful proton pump inhibitor (PPI) is the choice of treatment for antiplatelet-related peptic ulcers. The risk of cardiovascular complications and risk of gastric complication using antiplatelet agents should be evaluated individually.

Keywords

References

  1. Collaborative overview of randomised trials of antiplatelet therapy: I. prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients: Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106. https://doi.org/10.1136/bmj.308.6921.81
  2. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-2420. https://doi.org/10.1001/jama.288.19.2411
  3. Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents: the task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004;25:166-181. https://doi.org/10.1016/j.ehj.2003.10.013
  4. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 2004;127:395-402. https://doi.org/10.1053/j.gastro.2004.05.001
  5. Ng FH, Wong SY, Chang CM, et al. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther 2003;18:443-449. https://doi.org/10.1046/j.1365-2036.2003.01693.x
  6. Moukarbel GV, Signorovitch JE, Pfeffer MA, et al. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J 2009;30:2226-2232. https://doi.org/10.1093/eurheartj/ehp256
  7. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108:1682-1687. https://doi.org/10.1161/01.CIR.0000091201.39590.CB
  8. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006;55:1731-1738. https://doi.org/10.1136/gut.2005.080754
  9. Chan FK. Review: low-dose aspirin causes a small increase in gastrointestinal bleeding. ACP J Club 2007;146:13.
  10. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet 2009;374:1449-1461. https://doi.org/10.1016/S0140-6736(09)60938-7
  11. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002;16:779-786. https://doi.org/10.1046/j.1365-2036.2002.01230.x
  12. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Writing Committee. J Am Coll Cardiol 2008;52:1502-1517. https://doi.org/10.1016/j.jacc.2008.08.002
  13. Hsu PI. Esomeprazole plus aspirin compared with esomeprazole alone for the treatment of aspirin-related peptic ulcers/erosions. Gastroenterology 2011;140(Suppl 1):S79.
  14. Ng FH, Wong SY, Lam KF, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 2010;138:82-88. https://doi.org/10.1053/j.gastro.2009.09.063
  15. Schouten O, van Domburg RT, Bax JJ, et al. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol 2007;49:122-124. https://doi.org/10.1016/j.jacc.2006.10.004
  16. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005;352:238-244. https://doi.org/10.1056/NEJMoa042087
  17. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-973. https://doi.org/10.1056/NEJM200103293441304
  18. Chan FK. Primer: managing NSAID-induced ulcer complications: balancing gastrointestinal and cardiovascular risks. Nat Clin Pract Gastroenterol Hepatol 2006;3:563-573. https://doi.org/10.1038/ncpgasthep0610
  19. Cryer B. Management of patients with high gastrointestinal risk on antiplatelet therapy. Gastroenterol Clin North Am 2009;38:289-303. https://doi.org/10.1016/j.gtc.2009.03.005
  20. Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart 2011;97:797-802. https://doi.org/10.1136/hrt.2010.217547
  21. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from longterm low-dose aspirin use. N Engl J Med 2002;346:2033-2038. https://doi.org/10.1056/NEJMoa012877
  22. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009;374:119-125. https://doi.org/10.1016/S0140-6736(09)61246-0
  23. Ng FH, Wong SY, Lam KF, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 2010;138:82-88. https://doi.org/10.1053/j.gastro.2009.09.063
  24. Ibanez L, Vidal X, Vendrell L, Moretti U, Laporte JR; Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther 2006;23:235-242. https://doi.org/10.1111/j.1365-2036.2006.02759.x
  25. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-362. https://doi.org/10.1056/NEJMoa0809171
  26. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375. https://doi.org/10.1056/NEJMoa0808227
  27. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309-317. https://doi.org/10.1016/S0140-6736(08)61845-0
  28. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010;152:337-345. https://doi.org/10.7326/0003-4819-152-6-201003160-00003
  29. Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 2010;153:378-386. https://doi.org/10.7326/0003-4819-153-6-201009210-00005
  30. Van Boxel OS, van Oijen MG, Hagenaars MP, Smout AJ, Siersema PD. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol 2010;105:2430-2436. https://doi.org/10.1038/ajg.2010.334